ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1975

Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations

Mohanad Elfishawi1,2, Sally Elfishawi3, Ghada Mossallam3, Paul Norman4, Jill Hollenbach5, Maneesh Misra5, Gonzalo Montero Martin6, Helma de Bruin7, Leos Van de Pasch7, Erik Rozemuller7, Marcelo Fernandiz-Vina6, Adriana Abrudescu8 and Khaled Zaky9, 1Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, NY, 2Rheumatology, Kasr Alainy Hospital, Cairo University, Cairo, Egypt, 3Clinical pathology and Immunology laboatory, National Cancer Institute, Cairo University, Cairo, Egypt, 4Division of Personalized Medicine and Department of Immunology, University of Colorado School of Medicine, Denver, CO, 5Department of Neurology, University of California San Francisco, San Francisco, CA, 6Department of Pathology, Stanford University,School of medicine, Palo Alto, CA, 7GenDx, Utrecht, Netherlands, 8Internal Medicine and Rheumatology, Icahn School of Medicine at Mount Sinai, Queens Hospital center, NYC, NY, 9Rheumatology and Rehabilitation, Faculty of medicine, Al-Azhar University, Cairo, Egypt

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, Disease susceptibility, epidemiologic methods and human leukocyte antigens (HLA), Genetic Biomarkers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Genetics, Genomics and Proteomics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Behçet’s disease is a multisystem disease affecting young adults with variable vessel vasculitis as its underlying pathology. Previous studies in Behçet’s disease linked it to the Human Leucocytic antigens (HLA) class I molecules however the use of High-resolution Next Generation Sequencing (NGS) wasn’t adopted before for all HLA loci (both class I and II ) analysis along with the haplotype analysis. This study aims to identify the Behcet disease susceptibility with class I and II HLA alleles using NGS along with their haplotype analysis to help better understand the disease process and to find a possible association with disease manifestations and severity.

Methods:

Sixty patients from specified geographical distribution diagnosed according to the International Study Group (ISG) criteria for Behçet’s disease along with 160 normal geographically ethnic-matched controls were typed for the class I HLA alleles and from the control group, 40 control samples were typed for class II HLA alleles.

The work was a part of participation in the 17th International Histocompatibility and Immunogenetics Workshop (IHIWS) in the disease association component during which HLA was typed for patients and 40 control subjects at the allelic level by NGS high resolution typing for 11 loci (HLA-A, B, C, DRB1, DRB3/4/5, DQA1, DQB1, DPA1, DPB1). The control group was then expanded for an additional 120 control subjects typed for HLA class I loci (A, B and C) along with data analysis and haplotype analysis for the results.

Results:

Sixty patients were enrolled with mean age 35.28 (±9.82 years) with 54 males (90%). The main clinical manifestations were oral ulcers (100%), genital ulcers (100%), eye involvement (55%) neurological involvement (28%) and vascular involvement (35%). Furthermore, (33%) had bilateral visual acuity < or = 6/60 fulfilling the diagnosis of legal blindness

HLA class I alleles A*68:02:01,B*51:08:01,C*16:02:01 showed highest level of association with Behcet disease patients with an OR =3 (p=0.01) and OR=18.6 (p<0.0000001) and OR=6.7 (p<0.000001) respectively. As for HLA class I haplotypes HLA class I B*51:08, C*16:02 haplotype was highly associated with susceptibility (OR=17.7, p<0.000001). HLA class I B*51 and A*68 were significantly associated with legal blindness (OR=10.1, p<0.005) and (OR=8.1, p=0.023)

Conclusion:

Among the studied Behçet’s Patients, HLA-B*51:08:01 is the most frequent susceptibility allele in contrast to other reported populations. Risk of Severe ocular involvement progressing to the blindness of patients was more than 10 folds increased in HLA-B51 positive patients as compared to other patients. HLA-B51 together with HLA-A68 both hold the increased risk of blindness and permanent morbidity in patients with Behcet disease, which if known at diagnosis would modify treatment options in order to salvage the patients’ eyesight. Higher resolution analysis of HLA class I alleles and haplotypes specially HLA-B is valuable in knowing susceptibility and aiding in disease control and decreasing ocular morbidity in Behcet disease patients


Disclosure: M. Elfishawi, None; S. Elfishawi, None; G. Mossallam, None; P. Norman, None; J. Hollenbach, None; M. Misra, None; G. M. Martin, None; H. de Bruin, GenDX, 3; L. Van de Pasch, GenDx, 3; E. Rozemuller, Gendx, 1, 3; M. Fernandiz-Vina, None; A. Abrudescu, None; K. Zaky, None.

To cite this abstract in AMA style:

Elfishawi M, Elfishawi S, Mossallam G, Norman P, Hollenbach J, Misra M, Martin GM, de Bruin H, Van de Pasch L, Rozemuller E, Fernandiz-Vina M, Abrudescu A, Zaky K. Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/behcets-disease-lies-in-the-b-holder-new-associations-in-disease-susceptibility-and-manifestations/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/behcets-disease-lies-in-the-b-holder-new-associations-in-disease-susceptibility-and-manifestations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology